Clinical significance of antibiotics modified release oral formulations
- Authors: Leonova MV1, Mukhina MA1, Leonova MV1, Muchina MA1
-
Affiliations:
- Issue: No 11 (2009)
- Pages: 11-17
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/277291
- ID: 277291
Cite item
Full Text
Abstract
The authors studied clinical advantages of antibiotics modified release oral formulation, which are very important for clinical practice. Such antibiotics include azithromycin ER and clarithromycin ER. These formulations have special pharmacokinetic feature - delayed absorption in distal areas of gastrointestinal tract, what decreases the contact with motilin receptors and improves antibiotics tolerability. Because of the high tissue penetration optimal tissue concentration of such antibiotics are preserved for a long time. Modified release oral formulations allows to achieve better clinical results, increase tolerability and decrease the frequency of antibiotis dosing, that result in better patients compliance.
Keywords
References
- Harrison TS, Keam SJ. Azithromycin extended release: a review of its use in the treatment of acute bacterial sinusitis and community acquired pneumonia in US. Drugs 2007;67(5):773-92.
- Chandra R, Liu P, Breen JD, et al. Clinical pharmacokinetics and gastrointestinal tolerability of a novel extended-release microsphere formulation of azithromycin./ Clin.Pharmacokinet 2007;46(3):247-59.
- Drehobl MA, De Salco MC, Lewis DE, et al. Single-dose azithromycin microspheres vs clarithromycin extended release for the treatment of mild-to-moderate community-acquired pneumonia in adults. CHEST 2005;128:2230-37.
- Gotfried MH. Clarithromycin (Biaxin®) extended-release tablet: a therapeutic review. Expert Rev Anti-unfect Ther 2003;1(1):9-20.
- Guay DR, Gustavson LE, Devcich KJ, et al. Pharmacokinetics and tolerability of extended-release clarithromycin. Clin Ther 2001;23:566-77.
- Darkes MJM, Perry CM. Clarithromycin extended-release tablet: a review of its use in the management of respiratory tract infections. Am J Respir Med 2003;2(2):175-201.
- Gotfried MH, Danziger LH, Rodvold KA. Steady-state plasma amd bronchopulmonary characteristics of clarithromycin extended-release tablets in normal healthy adults subjects. J Antimicrob Chemotherapy 2003;52:450-56.
- Stein GE, Schooley S. Serum bactericidal activity of extended-release clarithromycin against macrolide-resistant strains of streptococcus pneumoniae. Pharmacother 2002;22(5):593-96.
- Weiss K, Vanjaka A. Canadian Clarithromycin Study Group on Bronchitis. An open-label randomized multicenter comparative study of the efficacy and safety of 7 days of treatment with clarithromycin extended-release tablets versus clarithromycin immediate-release tablets for the treatment of patients with acute bacterial exacerbation of chronic bronchitis. Clin Ther 2002;12:2105-22.
- Martinot J-B, Carr WD, Cullen S, et al. A comparative study of clarithromycin modified release and amoxicillin/clavulanic acid in the treatment of acute exacerbation of chronic bronchitis. Adv Ther 2001;18(1):1-11.
- Williams KN, Bishai WR. Clarithromycin extended-release in community-acquired respiratory tract infections. Expert Opin Pharmacother 2005;6(16):2867-76.
- Liou J-M, Chen C-Y, Wu M-S, et al. Comparative study of modified-release clarithromycin and immediate-release clarithromycin in the treatment of Helicobacter pillory-associated peptic ulcer disease. Hepatogastroenterology 2006;53:792-96.
- Laine L, Estrada R, Trujillo M, et al. Once-daily therapy for H.Pilory infection: a randomized comparison of four regimens. Am J Gastroenterol 1999;94:962-66.
- Shu KM, Kwok KM, Law SY, et al. One-week once-daily triple therapy of Helicobacter pilory - a pilot study. Hepatogastroenterology 2000;47:1624-26.
- http://www.pharmateca.ru/cgi-bin/statyi.pl?sid=2332&mid=1085056570&magid=175&full=1
Supplementary files
